ArticleEye (London, England)2025
The effect of treatment of primary congenital glaucoma on meibomian glands and tear film.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate meibomian gland (MG) and tear film alterations in treated primary congenital glaucoma (PCG) patients through a comparative study.
methodsWe conducted a comparative, cross-sectional study analysing eyes with treated PCG vs healthy eyes of age-matched children using the MediWorks Dry Eye Diagnostic System to perform a non-contact quantitative analysis. Seven ocular parameters were measured: non-invasive break-up time (NIBUT), tear meniscus height, lipid layer thickness, eyelid edge morphology, MG morphology, ocular surface staining, and conjunctival hyperaemia.
resultsOur study included 71 treated PCG eyes (42 patients) and 30 non-glaucomatous healthy eyes (30 patients). Thirty (21 patients) of the 71 treated PCG eyes (42.3%) were on topical glaucoma medications at the time of study enrolment. MG loss grade (1.3 ± 0.5 vs 0.1 ± 0.3, P < 0.001), mean first rupture NIBUT (7.2 ± 2.6 s vs 11.9 ± 2.4 s, P < 0.001), lipid layer grade (3.2 ± 0.6 vs 3.6 ± 0.5, P = 0.03), and prevalence of low tear meniscus height (46.5% vs 93.3%, P < 0.001) were all significantly altered in the treated PCG group as compared to healthy controls. Sub-group analyses revealed significantly worse MG and tear film parameters in treated PCG eyes on glaucoma medications vs treated PCG eyes not on glaucoma medications and treated PCG eyes not on glaucoma medications vs healthy controls. Glaucoma surgery was also associated with worse parameters.
conclusionIn this first study to evaluate MG and tear film parameters in treated PCG, significant differences were observed in the MG morphology and tear film parameters of eyes with treated PCG compared to the eyes of healthy children. Glaucoma medication use and glaucoma surgery were individually correlated with ocular surface disease in treated PCG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.